転移性去勢感受性前立腺癌患者におけるアパルタミド：無作為化二重盲検第III相TITAN試験の最終生存解析

N.ら（木曜日）はこの問題を研究した。

www.synapsesocial.com/papers/69dd278bf0cb8f4dd53591f8 — DOI: https://doi.org/10.1200/jco.20.03488

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Use and outcomes in men with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel in addition to androgen deprivation therapy (ADT): Analysis of real-world data in the United States (US).· 2020 · 3 citations
2. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I· 2020 · 262 citations
3. 611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)· 2020 · 21 citations
4. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group· 2008 · 2,234 citations
5. Adjusted survival curves with inverse probability weights· 2003 · 812 citations